查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1928589

血管內旋轉斑塊動脈粥狀硬化斑塊切除術裝置市場（按產品類型、技術、應用和最終用戶分類），全球預測（2026-2032）

Endovascular Rotational Atherectomy Devices Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年血管內旋轉斑塊動脈粥狀硬化斑塊切除術裝置市值為 4.4121 億美元，預計到 2026 年將成長至 4.7854 億美元，預計到 2032 年將達到 6.8593 億美元，複合年成長率為 6.50%。

關鍵市場統計數據
基準年 2025 4.4121億美元
預計年份：2026年 4.7854億美元
預測年份 2032 6.8593億美元
複合年成長率 (%) 6.50%

簡明扼要的行業概述，重點介紹臨床促進因素、設備發展歷程以及影響旋切動脈粥狀硬化斑塊切除術技術應用的不斷變化的生態系統。

血管內旋轉動脈粥狀硬化斑塊切除術裝置處於介入性心臟病學、周邊血管治療和醫療設備工程的關鍵交叉領域。這些裝置是專門用於修復鈣化病變並促進複雜動脈疾病患者成功再灌注的專用工具。可預測斑塊修復的臨床需求推動了裝置形狀、磨頭幾何形狀和輸送系統的迭代創新。如今，手術團隊在選擇動脈粥狀硬化斑塊切除術平台時會考慮療效、安全性和工作流程整合。

推動血管專科領域旋切動脈粥狀硬化斑塊切除術治療設備設計、臨床工作流程和價值導向應用的關鍵變革性產業趨勢

近年來，動脈粥狀硬化斑塊切除術裝置的研發、評估和臨床應用發生了變革性變化。首要變化是將術中影像和數據分析整合到決策流程中，使裝置選擇從主導直覺轉向實證實踐。這種整合正在改變裝置的規格，臨床醫生更傾向於選擇能夠與血管內影像設備實現可預測整合且具有明確手術結束標準的系統。

評估不斷變化的關稅政策和貿易趨勢對血管內器械價值鏈中製造、採購和策略決策的累積影響

關稅的徵收或貿易政策的調整將對設備的整個生命週期產生重大影響，涵蓋採購、製造、定價和分銷等各個環節。當金屬零件、精密儀器或進口子系統的關稅調整導致投入成本增加時，製造商面臨一個迫在眉睫的選擇：自行承擔成本、調整標價或重組籌資策略。短期內，毛利率可能會受到壓縮，促使製造商重新評估研發和生產擴張的資本配置。

將臨床適應症、設備架構、臨床環境和技術選擇與商業化和開發路徑聯繫起來的策略性細分洞察

分析市場區隔的細微差別，可以揭示臨床適應症、產品形式、臨床環境和系統結構如何相互作用，從而指導產品開發和商業化策略。在分析應用領域時，冠狀動脈疾病和周邊動脈疾病之間的臨床差異會直接影響器械的幾何形狀、鑽頭尺寸和介面相容性。在周邊動脈疾病領域，頸動脈手術、透析通路維護和下肢動脈再灌注等特殊需求需要專門的方法，以最大限度地矯正病變，同時最大限度地降低栓塞風險。

美洲、歐洲、中東和非洲以及亞太市場臨床應用、監管合規和商業化的區域趨勢和策略方法

區域趨勢對旋切動脈粥狀硬化斑塊切除術的臨床實務模式、監管環境和商業策略有顯著影響。在美洲，綜合醫療網路和三級醫療中心的高手術量往往推動著手術創新，因此，那些擁有完善的培訓項目、明確的報銷標準和強大的本地服務體系的器械更受青睞。因此，面向該地區的製造商通常會強調真實世界的結果和協作培訓計劃，以加速器械在各種臨床環境中的應用。

透過臨床證據、一體化手術方案和穩健的供應鏈策略實現差異化競爭，從而確立醫療器材領先地位。

該領域的競爭發展更取決於企業如何建構臨床證據、商業化和供應鏈韌性等能力，而非單純的產品等效性。主要企業透過持續投資於臨床證據的生成，並發表註冊研究和實用性研究的結果來脫穎而出，這些研究能夠證明手術在真實臨床人群中的益處。同樣重要的是，要建立健全的臨床醫生培訓計劃，以減少操作者的技術差異，並提高在臨床診療現場對設備性能的評估能力。

醫療設備製造商可採取切實可行的策略行動，以擴大證據產生規模、完善商業模式並加強供應鏈和夥伴關係關係。

產業領導者應優先考慮一系列切實可行的舉措，以加強臨床應用、提升商業性韌性並建立創新路徑。首先，應投資於針對性的真實世界證據項目，以解決冠狀動脈和周邊血管領域具有重大影響的臨床問題，並確保研究設計能夠涵蓋與臨床醫生、支付方和醫院管理者相關的終點指標。同時，拓展結合模擬、指導和數位化學習的臨床醫生培訓課程至關重要，這有助於減少操作差異，並加速在各種臨床環境中自信地應用相關技術。

結合專家對話、臨床文獻綜合、監管分析和檢驗的穩健混合方法研究確保了研究結果的可靠性。

這些研究結果所依據的研究方法結合了定性專家訪談和結構化的二次分析，以確保對臨床和商業性動態進行平衡的解讀。主要資料收集包括對介入性心臟病專家、血管專家、採購人員和監管顧問的深入訪談，以了解他們對器械性能、培訓需求和採購行為的現場觀點。此外，一個諮詢小組也參與了這些訪談，以檢驗新出現的主題，並對不同醫療機構的流程進行細緻入微的解讀。

臨床、營運和商業性需求的整合將決定哪些公司能夠在不斷發展的心房和周邊動脈動脈粥狀硬化斑塊切除術市場中獲得持續優勢。

血管內旋切動脈粥狀硬化斑塊切除術的市場環境呈現出快速的臨床創新、不斷發展的手術流程生態系統以及不斷變化的商業性需求等特徵。能夠滿足臨床醫生對可預測斑塊修飾的需求、能夠順利融入手術流程並擁有嚴謹的真實世界證據支持的器械，預計在冠狀動脈和周邊血管疾病的治療中都獲得更高的普及率。同時，商業性成功將越來越依賴提供一體化解決方案、向購買者證明其經濟價值以及在當前地緣政治和貿易不確定性下維持穩健的供應鏈的能力。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的血管內旋轉動脈粥狀硬化斑塊切除術裝置市場

  • 酒吧
  • 系統

9. 依技術分類的血管內旋轉斑塊動脈粥狀硬化斑塊切除術裝置市場

  • 恆速系統
  • 變速系統

第10章 依應用分類的血管內旋轉動脈粥狀硬化斑塊切除術裝置市場

  • 冠狀動脈疾病
  • 周邊動脈疾病
    • 頸動脈
    • 透析通路
    • 下肢動脈

第11章 依最終用戶分類的血管內旋轉動脈粥狀硬化斑塊切除術裝置市場

  • 門診手術中心
  • 心臟中心
  • 醫院
    • 公立醫院
    • 私立醫院

12. 各地區血管內動脈粥狀硬化斑塊切除術裝置市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 血管內旋轉斑塊動脈粥狀硬化斑塊切除術裝置市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國血管內旋轉斑塊動脈粥狀硬化斑塊切除術裝置市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國血管內動脈粥狀硬化斑塊切除術裝置市場

第16章：中國血管內動脈粥狀硬化斑塊切除術裝置市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AngioDynamics, Inc.
  • Avinger, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardiovascular Systems, Inc.
  • Cook Medical LLC
  • Koninklijke Philips NV
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Penumbra, Inc.
  • Shockwave Medical, Inc.
  • Straub Medical AG
  • Terumo Corporation
Product Code: MRR-92740D85F051

The Endovascular Rotational Atherectomy Devices Market was valued at USD 441.21 million in 2025 and is projected to grow to USD 478.54 million in 2026, with a CAGR of 6.50%, reaching USD 685.93 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 441.21 million
Estimated Year [2026] USD 478.54 million
Forecast Year [2032] USD 685.93 million
CAGR (%) 6.50%

A concise industry overview highlighting clinical drivers, device evolution, and the shifting ecosystem that shapes adoption of rotational atherectomy technologies

Endovascular rotational atherectomy devices occupy a critical intersection of interventional cardiology, peripheral vascular therapies, and medical device engineering. These devices are specialized tools used to modify calcified lesions and facilitate successful revascularization in patients with complex arterial disease. The clinical imperative for predictable plaque modification has driven iterative innovation in device form factors, burr geometries, and delivery systems, and today procedural teams weigh efficacy, safety, and workflow integration when selecting an atherectomy platform.

Clinical adoption is shaped by several converging forces. Procedural volume growth for complex coronary and peripheral interventions, rising prevalence of vascular calcification in aging and comorbid populations, and a heightened focus on limb salvage pathways have combined to prioritize technologies that deliver consistent lesion debulking while minimizing distal embolization and procedural complications. Regulatory pathways and payer engagement continue to influence the speed of adoption, and multidisciplinary care teams increasingly evaluate device performance through the twin lenses of clinical outcomes and cost of care. Consequently, device manufacturers are investing in real-world evidence generation, training programs, and supply chain optimization to support sustained clinical uptake.

Looking ahead, the ecosystem around these devices is evolving beyond hardware alone. Adjunctive imaging, atherectomy-compatible guidewires and catheters, and procedural decision-support frameworks are emerging as complementary enablers. As a result, stakeholders across clinical, commercial, and regulatory domains are recalibrating their strategies to capture value from an integrated procedural model rather than a single-device sale. This trend elevates the importance of evidence-based positioning, user-centric training, and partnerships that bridge the gap between device performance in controlled studies and outcomes in routine clinical practice.

Key transformative industry trends driving device design, clinical workflows, and value-based adoption in rotational atherectomy care across vascular specialties

Recent years have seen transformative shifts that affect how rotational atherectomy devices are developed, evaluated, and adopted in clinical settings. The first major shift is the integration of procedural imaging and data analytics into the decision-making workflow, which moves device selection from intuition-driven to evidence-supported practice. This integration is altering device specifications, with clinicians favoring systems that offer predictable interactions with intravascular imaging modalities and clear procedural endpoints.

A second pivotal change is the movement toward modular procedural ecosystems rather than single-point solutions. Device vendors are expanding their value propositions to include training programs, bundled disposables, and service models that support operating room efficiency. Accordingly, hospitals and ambulatory centers increasingly prioritize total-procedure cost and throughput, prompting manufacturers to redesign packaging, sterilization logistics, and support services to fit different care settings.

Third, regulatory scrutiny and post-market surveillance have intensified, compelling companies to generate robust real-world evidence and to engage proactively with payers and health technology assessment bodies. This heightened oversight accelerates the adoption curve for devices that demonstrate consistent safety in heterogeneous patient populations. Finally, cross-disciplinary collaboration between peripheral and coronary intervention specialists is redefining procedural best practices, encouraging design innovations that cater to diverse lesion anatomies and access strategies. Taken together, these trends are reshaping competitive dynamics and elevating the importance of clinical, operational, and economic arguments in market positioning.

Assessing how evolving tariff policies and trade dynamics cumulatively influence manufacturing, sourcing, and strategic decisions across the endovascular device value chain

The imposition of tariffs and changes in trade policy can have material effects across the device lifecycle, from component sourcing and manufacturing to pricing and distribution. When tariff adjustments increase input costs on metallic components, precision instruments, or imported subsystems, manufacturers face immediate choices: absorb the cost, adjust list prices, or reconfigure sourcing strategies. In the short term this can compress gross margins and prompt reassessment of capital allocation for R&D and production scaling.

Over time, tariffs encourage supply chain localization and diversification. Device firms may accelerate investments in regional manufacturing hubs or qualify alternative suppliers to mitigate exposure to tariff volatility. Such shifts have implications for lead times, quality control, and inventory strategies, requiring tighter coordination between procurement, regulatory affairs, and quality systems. Clinicians and health systems may experience indirect impacts through procurement cycles and vendor contract negotiations as firms seek to preserve market access while protecting commercial viability.

A cumulative tariff effect also influences strategic partnerships and M&A dynamics. Companies looking to secure supply resilience or to gain localized manufacturing capabilities may pursue targeted acquisitions or joint ventures. In parallel, increased unit costs can amplify the importance of delivering demonstrable clinical benefits that justify price adjustments, reinforcing the imperative for rigorous outcomes data and payer engagement. Ultimately, tariff-driven cost pressures reshape competition by privileging firms with flexible manufacturing footprints, vertically integrated supply chains, and strong clinician and payer relationships that can absorb or justify price transitions.

Strategic segmentation insights that connect clinical indications, device architectures, care settings, and technological choices to commercialization and development pathways

A nuanced view of market segmentation illuminates how clinical indications, product form factors, care settings, and system architectures interact to guide development and commercialization strategies. When analyzing application areas, the clinical distinction between coronary artery disease and peripheral arterial disease has direct implications for device geometry, burr sizing, and interface compatibility; within peripheral arterial disease, specialized needs for carotid artery procedures, dialysis access maintenance, and lower limb artery revascularization demand tailored approaches to minimize embolic risk while maximizing lesion modification.

Product-type differentiation between burrs and systems informs a split strategy for companies that wish to support both consumable demand and capital equipment sales. Burr design innovations can be positioned as upgrades to existing capital platforms, while system-level innovation can create lock-in through proprietary interfaces and integrated disposables. End-user segmentation across ambulatory surgical centers, cardiac centers, and hospitals requires manufacturers to align training, service, and reimbursement support to the operational realities of each setting; within hospitals, the distinction between government and private institutions affects procurement cycles, contracting flexibility, and expectations for vendor-managed inventory.

Finally, technology segmentation between constant speed systems and variable speed systems highlights divergent performance philosophies: constant speed approaches prioritize procedural simplicity and predictability, whereas variable speed architectures emphasize adaptability to lesion morphology and operator preference. These technological choices cascade into clinician training requirements, maintenance schedules, and downstream accessories, and therefore they should inform product roadmaps and commercialization playbooks simultaneously rather than in isolation.

Regional dynamics and strategic approaches for clinical adoption, regulatory engagement, and commercialization across Americas, EMEA, and Asia-Pacific markets

Regional dynamics exert a powerful influence on clinical practice patterns, regulatory landscapes, and commercial strategies for rotational atherectomy devices. In the Americas, procedural innovation is often driven by integrated care networks and high procedural volumes in tertiary centers, which favor devices supported by robust training programs, reimbursement clarity, and local service infrastructure. Consequently, manufacturers targeting this region frequently emphasize real-world outcomes and collaborative training initiatives to accelerate adoption across diverse care settings.

In Europe, Middle East & Africa, heterogeneity across health systems requires flexible market entry strategies that balance centralized regulatory approvals with region-specific evidence generation and distribution models. Buyers in these regions may prioritize cost-effectiveness and long-term service agreements, and therefore suppliers must be prepared to demonstrate durable clinical benefit and offer adaptable commercial terms. In the Asia-Pacific region, rapid infrastructure investment, increasing procedural capacity, and growing emphasis on minimally invasive therapies create opportunities for both established and emerging players; success here often depends on local regulatory navigation, partnerships with regional distributors, and supply chain responsiveness to varying procurement cycles.

Across all regions, differences in physician training pathways, reimbursement frameworks, and hospital procurement processes mean that a one-size-fits-all approach is insufficient. Manufacturers that tailor their clinical education, value communication, and logistical support to regional needs while maintaining high standards for evidence generation and device quality will be best positioned to navigate the diverse regulatory and commercial terrains that characterize global markets.

Competitive differentiation driven by clinical evidence, integrated procedural solutions, and resilient supply chain strategies shaping leadership in the device landscape

Competitive dynamics in this sector are shaped less by pure product parity and more by how companies assemble capabilities across clinical evidence, commercialization, and supply resilience. Leading firms are differentiating through continuous investment in clinical evidence generation, publishing outcomes from registries and pragmatic studies that demonstrate procedural benefits across real-world cohorts. Equally important are robust clinician training programs that reduce variability in operator technique and thereby improve perceived device performance at the point of care.

From a commercial perspective, companies are enhancing value propositions by bundling capital systems with consumable burrs and by offering flexible purchasing models, including managed service agreements and outcome-linked contracts. Strategic partnerships with imaging providers and peripheral device makers are emerging as a way to create integrated procedural solutions that appeal to high-volume centers. On the manufacturing front, firms that have diversified supplier bases and multiple production sites demonstrate greater resilience to supply shocks, enabling steadier product availability and more predictable service timelines.

Intellectual property portfolios and regulatory track records remain important barriers to entry, but the competitive landscape also rewards nimble innovators who can rapidly translate clinical feedback into incremental device improvements. Finally, the ability to navigate complex reimbursement environments and to articulate a clear economic case for device adoption often separates successful commercial rollouts from stalled ones, underscoring the need for multidisciplinary alignment between clinical affairs, health economics, and sales operations.

Practical strategic actions for device makers to scale evidence generation, refine commercial models, and strengthen supply chain and partnership capabilities

Industry leaders should prioritize a set of actionable initiatives to strengthen clinical adoption, commercial resilience, and innovation pathways. First, invest in targeted real-world evidence programs that address high-impact clinical questions across coronary and peripheral indications, and ensure that study designs capture endpoints relevant to clinicians, payers, and hospital administrators. Complementary to this, expand clinician training programs that combine simulation, proctoring, and digital learning to reduce performance variability and to accelerate confident use in diverse care settings.

Second, re-evaluate commercial models to include bundled offerings, flexible procurement options, and service agreements that align with hospital and ambulatory center budgeting cycles. This approach can reduce friction at the point of purchase and support longer-term revenue predictability. Third, fortify supply chains by qualifying multiple suppliers for critical components, exploring regional manufacturing partnerships, and developing contingency inventory strategies to minimize disruption from trade policy shifts. Fourth, pursue interoperable device architectures and partnerships with imaging and accessory providers to create compelling integrated procedural ecosystems that enhance clinical workflow and differentiate product portfolios.

Finally, engage proactively with payers and health technology assessment bodies to build a transparent economic narrative that links device performance to reductions in complication rates, procedure times, or downstream interventions. Taken together, these actions will sharpen competitive positioning and enable companies to translate technical innovation into measurable clinical and commercial outcomes.

Robust mixed-methods research design combining expert engagement, clinical literature synthesis, regulatory analysis, and triangulation to ensure credible insights

The research approach underpinning these insights combines qualitative expert engagement with structured secondary analysis to ensure balanced interpretation of clinical and commercial dynamics. Primary data collection included in-depth interviews with interventional cardiologists, vascular specialists, procurement leaders, and regulatory consultants to capture frontline perspectives on device performance, training needs, and purchasing behaviors. These conversations were supplemented by advisory panels that validated emergent themes and provided nuanced interpretation of procedural workflows across care settings.

Secondary investigation encompassed peer-reviewed clinical literature, regulatory filings, device IFUs, and procedure registries to triangulate clinical claims and to understand device design evolution. In addition, analysis of procurement trends and hospital purchasing practices informed the commercial and regional insights. Data quality was reinforced through cross-validation methods, comparing clinician feedback against published outcomes and device labeling to identify consistent performance signals and potential gaps.

Throughout the process, methodological safeguards were applied to mitigate bias, including the use of independent expert reviewers and transparent documentation of data sources and analytical assumptions. This multilayered approach ensures that the conclusions reflect both the lived experience of clinical stakeholders and the documented technical and regulatory context that shapes device deployment.

Synthesis of clinical, operational, and commercial imperatives that determine which firms will secure sustainable advantage in the evolving atrial and peripheral atherectomy landscape

The landscape for endovascular rotational atherectomy devices is defined by rapid clinical innovation, evolving procedural ecosystems, and shifting commercial imperatives. Devices that align with clinician needs for predictable plaque modification, integrate smoothly into procedural workflows, and are supported by rigorous real-world evidence will command greater consideration in both coronary and peripheral indications. At the same time, commercial success will increasingly depend on the ability to offer integrated solutions, to demonstrate economic value to purchasers, and to maintain resilient supply chains in the face of geopolitical and trade uncertainties.

Stakeholders that proactively invest in clinician education, evidence generation, and flexible commercialization models will be better positioned to convert technical differentiation into durable market advantage. Likewise, regional sensitivity in regulatory engagement and distribution strategy will be essential for expanding global reach without compromising compliance or service quality. In summary, the convergence of clinical, operational, and economic drivers creates both challenges and opportunities for device makers; those that execute with strategic clarity and operational rigor will capture disproportionate value as the sector continues to mature.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endovascular Rotational Atherectomy Devices Market, by Product Type

  • 8.1. Burrs
  • 8.2. Systems

9. Endovascular Rotational Atherectomy Devices Market, by Technology

  • 9.1. Constant Speed System
  • 9.2. Variable Speed System

10. Endovascular Rotational Atherectomy Devices Market, by Application

  • 10.1. Coronary Artery Disease
  • 10.2. Peripheral Arterial Disease
    • 10.2.1. Carotid Artery
    • 10.2.2. Dialysis Access
    • 10.2.3. Lower Limb Artery

11. Endovascular Rotational Atherectomy Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Centers
  • 11.3. Hospitals
    • 11.3.1. Government Hospitals
    • 11.3.2. Private Hospitals

12. Endovascular Rotational Atherectomy Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endovascular Rotational Atherectomy Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endovascular Rotational Atherectomy Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Endovascular Rotational Atherectomy Devices Market

16. China Endovascular Rotational Atherectomy Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AngioDynamics, Inc.
  • 17.7. Avinger, Inc.
  • 17.8. B. Braun Melsungen AG
  • 17.9. Becton, Dickinson and Company
  • 17.10. Biotronik SE & Co. KG
  • 17.11. Boston Scientific Corporation
  • 17.12. Cardiovascular Systems, Inc.
  • 17.13. Cook Medical LLC
  • 17.14. Koninklijke Philips N.V.
  • 17.15. Medtronic plc
  • 17.16. Merit Medical Systems, Inc.
  • 17.17. Penumbra, Inc.
  • 17.18. Shockwave Medical, Inc.
  • 17.19. Straub Medical AG
  • 17.20. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY BURRS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY BURRS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY BURRS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CONSTANT SPEED SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CONSTANT SPEED SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CONSTANT SPEED SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY VARIABLE SPEED SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY VARIABLE SPEED SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY VARIABLE SPEED SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CAROTID ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CAROTID ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CAROTID ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY DIALYSIS ACCESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY DIALYSIS ACCESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY DIALYSIS ACCESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY LOWER LIMB ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY LOWER LIMB ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY LOWER LIMB ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)